Neoleukin Therapeutics to Host Investor R&D Showcase Highlighting De Novo Protein Therapeutics
June 15, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, June 15, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Appointment of Erin Lavelle to Board of Directors
June 01, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, June 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Present at Jefferies Virtual Healthcare Conference
May 27, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, May 27, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 15, 2020 07:00 ET
|
Neoleukin Therapeutics, Inc.
-Preclinical Data on Lead Immunotherapy Candidate NL-201 Including Immunogencity Results in Non-Human Primates--Novel Conditional Activation Platform Enabled by De Novo Protein Technology--Preclinical...
Neoleukin Therapeutics to Present at Virtual BofA Securities 2020 Health Care Conference
May 07, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update
May 06, 2020 16:01 ET
|
Neoleukin Therapeutics, Inc.
- IND submission for NL-201 anticipated by end of 2020 - - Three abstracts to be presented at AACR-II - SEATTLE, May 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”)...
Neoleukin Therapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held May 5, 2020
April 16, 2020 16:05 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, April 16, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Provides Update on COVID-19 Impact on Corporate and Clinical Development Activities
April 09, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, April 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Year End Financial Results
March 12, 2020 16:01 ET
|
Neoleukin Therapeutics, Inc.
- NL-201 IND Submission Expected by End of 2020 - - Company to host Conference Call Today, March 12, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern - SEATTLE, March 12, 2020 (GLOBE NEWSWIRE) --...
Neoleukin Therapeutics to Host 2019 Financial Results Conference Call and Webcast on March 12, 2020
March 05, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, March 05, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...